Jubilant Ingrevia Limited (JUBLINGREA.NS)
INR 800.95
(-4.21%)
INR 800.95
(-4.21%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 9.16 Billion INR | -55.91% |
| 2022 | 21.58 Billion INR | 10.38% |
| 2021 | 19.55 Billion INR | 604.63% |
| 2020 | 2.77 Billion INR | 0.0% |
| 2019 | - INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 5.22 Billion INR | 8.89% |
| 2024 Q1 | 2.37 Billion INR | -0.76% |
| 2023 Q2 | 5.05 Billion INR | -2.43% |
| 2023 FY | 9.51 Billion INR | -55.91% |
| 2023 Q4 | 2.39 Billion INR | -47.05% |
| 2023 Q3 | 4.51 Billion INR | -10.67% |
| 2023 Q1 | 5.18 Billion INR | 7.65% |
| 2022 Q2 | 5.84 Billion INR | 6.21% |
| 2022 Q1 | 5.5 Billion INR | 45.96% |
| 2022 FY | 21.58 Billion INR | 10.38% |
| 2022 Q4 | 4.81 Billion INR | -11.27% |
| 2022 Q3 | 5.42 Billion INR | -7.12% |
| 2021 FY | 19.55 Billion INR | 604.63% |
| 2021 Q4 | 3.76 Billion INR | -31.28% |
| 2021 Q3 | 5.48 Billion INR | 10.85% |
| 2021 Q2 | 4.94 Billion INR | -11.49% |
| 2021 Q1 | 5.59 Billion INR | -17.66% |
| 2020 Q4 | 6.78 Billion INR | 200.0% |
| 2020 Q3 | -6.78 Billion INR | -139.52% |
| 2020 Q2 | 17.17 Billion INR | 0.0% |
| 2020 FY | 2.77 Billion INR | 0.0% |
| 2019 FY | - INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Biocon Limited | 91.73 Billion INR | 90.008% |
| Blue Jet Healthcare Limited | 3.15 Billion INR | -190.134% |
| Concord Biotech Limited | 7.56 Billion INR | -21.171% |
| Dishman Carbogen Amcis Limited | 4.9 Billion INR | -86.915% |
| Lyka Labs Limited | 145.95 Million INR | -6180.113% |
| Panacea Biotec Limited | 1.42 Billion INR | -542.008% |
| Piramal Pharma Limited | 24.47 Billion INR | 62.543% |
| SMS Lifesciences India Limited | 329.57 Million INR | -2681.134% |
| Supriya Lifescience Limited | 2.65 Billion INR | -245.65% |
| Syngene International Limited | 12.43 Billion INR | 26.307% |
| TAKE Solutions Limited | 183.42 Million INR | -4897.247% |
| Zota Health Care Limited | 332.52 Million INR | -2656.453% |